Omeros

OMER · NASDAQ

$16.55+$0.20 (+1.22%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $16.35

Latest news

Press releaseOct 20, 4:02 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NewsOct 16, 8:02 AM ETAvi Kapoor
Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
NewsOct 16, 6:55 AM ETDylan Berman
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
NewsOct 16, 6:22 AM ET
Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Press releaseOct 16, 6:19 AM ETBusiness Wire
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
NewsSep 22, 1:51 PM ETVandana Singh
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
NewsAug 13, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsAug 13, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsAug 12, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsAug 12, 4:06 PM ET
Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate
Press releaseAug 12, 4:02 PM ETBusiness Wire
Omeros Corporation Reports Second Quarter 2026 Financial Results
Press releaseAug 10, 8:00 AM ETBusiness Wire
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Press releaseAug 3, 8:30 AM ETBusiness Wire
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
Press releaseJul 30, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Press releaseJul 28, 4:50 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NewsJul 27, 10:35 AM ETAvi Kapoor
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
Press releaseJul 23, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Press releaseJul 21, 12:56 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
Press releaseJul 9, 7:57 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Press releaseJul 8, 9:34 AM ETGlobe Newswire
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
Press releaseJul 7, 5:47 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Press releaseJul 6, 7:57 PM ETBusiness Wire
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
Press releaseJul 1, 8:11 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NewsJun 26, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsJun 26, 12:17 PM ETAvi Kapoor
Crude Oil Falls 4%; US Consumer Sentiment Rises In June
NewsJun 26, 11:16 AM ETVandana Singh
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide
NewsJun 26, 8:33 AM ET
Omeros Gets EMA CHMP Negative Opinion On Narsoplimab In TA‑TMA; Co. To Request Re‑Examination And Seek Ad Hoc Expert Group Review
Press releaseJun 26, 8:30 AM ETBusiness Wire
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
NewsJun 26, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseJun 15, 8:30 AM ETBusiness Wire
Omeros Announces Webcast Details for Annual Meeting of Shareholders
Press releaseMay 13, 4:02 PM ETBusiness Wire
Omeros Corporation Reports First Quarter 2026 Financial Results
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
Press releaseMay 11, 4:02 PM ETBusiness Wire
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
Press releaseApr 20, 7:00 AM ETGlobe Newswire
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Press releaseApr 16, 8:45 AM ETBusiness Wire
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
NewsMar 31, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 31, 4:02 PM ETBusiness Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Press releaseMar 26, 8:45 AM ETBusiness Wire
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
NewsDec 24, 11:06 AM ETAvi Kapoor
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
NewsOct 17, 12:17 PM ETAvi Kapoor
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings
NewsOct 15, 2:20 PM ETAvi Kapoor
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
NewsOct 15, 10:17 AM ETAvi Kapoor
S&P 500 Gains 1%; Bank of America Posts Upbeat Earnings
NewsJun 10, 12:53 PM ETNabaparna Bhattacharya
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Omeros Q2 Adj. EPS $0.02 Beats $(0.27) Estimate, Sales $28.529M Beat $12.700M Estimate

Omeros Corporation Reports Second Quarter 2026 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

12 Health Care Stocks Moving In Friday's Intraday Session

Crude Oil Falls 4%; US Consumer Sentiment Rises In June

FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

Omeros Gets EMA CHMP Negative Opinion On Narsoplimab In TA‑TMA; Co. To Request Re‑Examination And Seek Ad Hoc Expert Group Review

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

12 Health Care Stocks Moving In Friday's Pre-Market Session

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Corporation Reports First Quarter 2026 Financial Results

Earnings Scheduled For May 13, 2026

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

12 Health Care Stocks Moving In Tuesday's After-Market Session

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday

Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

S&P 500 Gains 1%; Bank of America Posts Upbeat Earnings

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision